| References |
Top |
| REF 1 |
Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity. Oncogene. 2000 Feb 24;19(9):1147-52.
|
| REF 2 |
Stabilization of MyoD by direct binding to p57(Kip2). J Biol Chem. 2000 Jun 23;275(25):18767-76.
|
| REF 3 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 4 |
The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain. J Biol Chem. 2003 Nov 7;278(45):44255-64.
|
| REF 5 |
SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology. 2009 Nov;137(5):1816-26.e1-10.
|
| REF 6 |
Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10231-6.
|
